Allogene Therapeutics (ALLO) Stock Overview
A clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ALLO Community Fair Values
Create NarrativeSee what 19 others think this stock is worth. Follow their fair value or set your own to get alerts.
Allogene Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.24 |
| 52 Week High | US$3.78 |
| 52 Week Low | US$0.86 |
| Beta | 0.43 |
| 1 Month Change | -6.77% |
| 3 Month Change | 12.73% |
| 1 Year Change | -54.41% |
| 3 Year Change | -86.72% |
| 5 Year Change | -95.54% |
| Change since IPO | -95.04% |
Recent News & Updates
Recent updates
Allogene Therapeutics: Important Catalysts Guided For Early 2026
Aug 14Shareholders May Find It Hard To Justify Increasing Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) CEO Compensation For Now
Jun 12
Here's Why We're Watching Allogene Therapeutics' (NASDAQ:ALLO) Cash Burn Situation
Apr 02Allogene Therapeutics: Disrupting CAR-T With A Scalable Model
Feb 25Allogene Therapeutics: Showing Promise Despite Some Shaky Safety
Dec 10Is Allogene Therapeutics (NASDAQ:ALLO) In A Good Position To Invest In Growth?
Nov 22Allogene Therapeutics: Cema-Cel Promising Among Innovative CAR T-Cell Therapies
Aug 27Allogene: Two End Of 2024 Data Readouts With Improved Allogeneic CAR-T Products
Jun 12We Discuss Why Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) CEO Compensation May Be Closely Reviewed
May 30Allogene Therapeutics: 2024 Platform Vision Sings Mid-Term Upside
Apr 01We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully
Mar 01We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully
Jun 09We're Hopeful That Allogene Therapeutics (NASDAQ:ALLO) Will Use Its Cash Wisely
Feb 22Shareholder Returns
| ALLO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.3% | 3.1% | 0.5% |
| 1Y | -54.4% | 3.9% | 20.1% |
Return vs Industry: ALLO underperformed the US Biotechs industry which returned 3.9% over the past year.
Return vs Market: ALLO underperformed the US Market which returned 20% over the past year.
Price Volatility
| ALLO volatility | |
|---|---|
| ALLO Average Weekly Movement | 8.8% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ALLO has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ALLO's weekly volatility has decreased from 14% to 9% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 228 | David Chang | allogene.com |
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma.
Allogene Therapeutics, Inc. Fundamentals Summary
| ALLO fundamental statistics | |
|---|---|
| Market cap | US$275.13m |
| Earnings (TTM) | -US$236.91m |
| Revenue (TTM) | n/a |
Is ALLO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALLO income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$180.04m |
| Gross Profit | -US$180.04m |
| Other Expenses | US$56.87m |
| Earnings | -US$236.91m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Nov 06, 2025
| Earnings per share (EPS) | -1.07 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ALLO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/02 15:23 |
| End of Day Share Price | 2025/10/31 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Allogene Therapeutics, Inc. is covered by 29 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| Shanshan Xu | Berenberg |
| Jason Matthew Gerberry | BofA Global Research |